Cipla Limited is a leading Indian pharmaceutical company. It operates in over 80 countries. The company produces generic and specialty medicines for respiratory, cardiovascular, oncology, and diabetes therapies. Founded in 1935, Cipla is known for affordable medicines and a strong distribution network.
Stock Performance
On Friday, October 24, Cipla shares fell 3%. This happened despite the company announcing a partnership with Eli Lilly to market a weight-loss drug in India under a new brand. However, analysts said the stock’s recent gains had already priced in much of the positive news.
Earlier, the stock had gained over 7.5% in five sessions. It had dropped 1% on Thursday. Consequently, Friday’s decline continued the trend of profit-taking.
Cipla-Eli Lilly Deal: Key Details
Under the agreement, Eli Lilly will supply the drug. Cipla will market it under the brand ‘Yurpeak’. Additionally, the drug will be priced similar to Mounjaro. It will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
The deal targets the GLP-1 agonist market. This drug class treats diabetes and obesity. Elara Capital analysts called the move innovative. They estimate the Indian market could exceed $1 billion in the next four years.
Moreover, Cipla expects the partnership to contribute about 3% to its domestic revenue. It may add 1.5% to overall EBITDA within three years. Nuvama Research projects FY26E/27E sales of ₹3.6–3.7 billion from this segment. As a result, Cipla is positioned as a leader in India’s semaglutide market.
Analysts’ Perspectives
Despite the positive outlook, analysts expect limited near-term upside.
Elara Capital maintained an ‘accumulate’ rating with a target price of ₹1,670. The firm will review estimates after Q2 earnings on October 30, 2025.
Nuvama Research slightly raised revenue and PAT forecasts for FY26E/FY27E. They increased the target price to ₹1,725 and retained a ‘hold’ rating. In contrast, analysts said the recent dip mainly reflects profit booking as investors await quarterly results.
Industry Context
India’s obesity and diabetes markets are growing fast. Furthermore, the entry of global players like Eli Lilly will increase competition. However, Cipla’s strong distribution network and field presence give it an edge. Ultimately, pricing, adoption rates, and patient awareness will determine Yurpeak’s success.
Conclusion
The Eli Lilly deal strengthens Cipla’s portfolio. Nevertheless, the recent stock rally prompted profit-taking, causing a 3% drop. In the long term, Cipla is likely to gain in revenue, EBITDA, and market share from this strategic partnership.
